Ami Organics Ltd
NSE:AMIORG
Ami Organics Ltd
Ami Organics Ltd. engages in the development and commercialization of pharmaceutical intermediate products. The company is headquartered in Surat, Gujarat and currently employs 561 full-time employees. The company went IPO on 2021-09-14. These specialty chemicals with varied end usage, focus on the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredient (APIs) and new chemical entity (NCEs). The company manufactures pharma intermediates for certain APIs, including dolutegravir, trazodone, entacapone, nintedanib and rivaroxaban. The pharma intermediates, which the Company manufactures have application in certain high-growth therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. The company has developed and commercialized over 450 pharma intermediates for APIs and NCEs across 17 therapeutic areas. Its specialty chemicals have applications in the agrochemicals and fine chemicals industries. The firm supplies its products to more than 150 customers directly in India.
Ami Organics Ltd. engages in the development and commercialization of pharmaceutical intermediate products. The company is headquartered in Surat, Gujarat and currently employs 561 full-time employees. The company went IPO on 2021-09-14. These specialty chemicals with varied end usage, focus on the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredient (APIs) and new chemical entity (NCEs). The company manufactures pharma intermediates for certain APIs, including dolutegravir, trazodone, entacapone, nintedanib and rivaroxaban. The pharma intermediates, which the Company manufactures have application in certain high-growth therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. The company has developed and commercialized over 450 pharma intermediates for APIs and NCEs across 17 therapeutic areas. Its specialty chemicals have applications in the agrochemicals and fine chemicals industries. The firm supplies its products to more than 150 customers directly in India.
Strong Revenue Growth: Q1 FY '26 revenue grew 17.3% year-on-year to INR 2,072 million, driven mainly by advanced pharmaceutical intermediates.
Margin Expansion: Gross margin rose sharply by 1,117 bps YoY to 53.2%, and EBITDA margin increased 785 bps YoY to 24.6%, reflecting cost optimization and a favorable product mix.
Profit Surge: PAT for the quarter tripled to INR 44 crores from INR 14.7 crores YoY, with PAT margin expanding to 21.2%.
Guidance Reiterated: Management reaffirmed 25% revenue growth and stronger margin guidance for FY '26.
Key Projects on Track: CapEx for new battery chemicals (electrolyte additives) and semiconductor JV in Korea are progressing; commercial contributions from both expected by Q4 FY '26 and late 2026/early 2027 respectively.
CDMO Pipeline: Three new CDMO projects expected to commercialize by Q4 FY '26, each with INR 50–100 crore revenue potential.
Export Focus: Battery chemicals growth is not dependent on delayed Indian EV projects, with exports driving demand.
Cash & CapEx: Strong operational cash flow of INR 94.6 crores; CapEx for the year expected at INR 250 crores, fully funded by cash on hand.
